Seer filed a patent infringement lawsuit against Nanomics Biotechnology, asserting multiple patents covering Seer’s nanoparticle-based protein enrichment technology used in its Proteograph product suite. The complaint follows a Patent Trial and Appeal Board decision that invalidated some claims of one patent while upholding several others Seer believes remain protective. Seer alleges Nanomics’ nanoparticle-based enrichment products and workflows infringe, seeking monetary damages and injunctive relief. The dispute includes prior PTAB challenges filed by Bruker subsidiaries PreOmics and Biognosys. Nanomics markets both proteomic services and enrichment kits, with an automated workstation tied to protein enrichment workflows. Bruker’s Biognosys group characterized the PTAB outcome as “clearing the field” for its technologies and continued development. For the proteomics tools market, IP litigation is a direct determinant of platform adoption, interoperability, and pricing, especially in nanoparticle enrichment—an area critical for low-abundance protein measurement.